New Drugs Stir Debate on Rules of Clinical Trials

September 20, 2010

The New York Times

Controlled trials have for decades been considered for proving a drug's value before it can go to market. But the continuing trial of the melanoma drug, PLX4032, has ignited an anguished debate among oncologists about whether a controlled trial that measures a drug's impact on extending life is still the best method for evaluating hundreds of genetically targeted cancer drugs being developed... Read More